Cansino Biologics Inc (688185) - Net Assets

Latest as of September 2025: CN¥4.93 Billion CNY ≈ $721.61 Million USD

Based on the latest financial reports, Cansino Biologics Inc (688185) has net assets worth CN¥4.93 Billion CNY (≈ $721.61 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥7.30 Billion ≈ $1.07 Billion USD) and total liabilities (CN¥2.37 Billion ≈ $346.78 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Cansino Biologics Inc to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥4.93 Billion
% of Total Assets	67.54%
Annual Growth Rate	47.92%
5-Year Change	-19.04%
10-Year Change	N/A
Growth Volatility	120.73

Cansino Biologics Inc - Net Assets Trend (2016–2024)

This chart illustrates how Cansino Biologics Inc's net assets have evolved over time, based on quarterly financial data. Also explore 688185 total assets for the complete picture of this company's asset base.

Annual Net Assets for Cansino Biologics Inc (2016–2024)

The table below shows the annual net assets of Cansino Biologics Inc from 2016 to 2024. For live valuation and market cap data, see Cansino Biologics Inc market cap and net worth.

Year	Net Assets	Change
2024-12-31	CN¥4.92 Billion ≈ $719.24 Million	-7.04%
2023-12-31	CN¥5.29 Billion ≈ $773.72 Million	-27.03%
2022-12-31	CN¥7.25 Billion ≈ $1.06 Billion	-15.24%
2021-12-31	CN¥8.55 Billion ≈ $1.25 Billion	+40.80%
2020-12-31	CN¥6.07 Billion ≈ $888.36 Million	+312.84%
2019-12-31	CN¥1.47 Billion ≈ $215.18 Million	+192.75%
2018-12-31	CN¥502.32 Million ≈ $73.50 Million	-17.29%
2017-12-31	CN¥607.33 Million ≈ $88.87 Million	+183.17%
2016-12-31	CN¥214.47 Million ≈ $31.38 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Cansino Biologics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 180121285800.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Common Stock	CN¥247.45 Million	5.04%
Other Comprehensive Income	CN¥26.57 Million	0.54%
Other Components	CN¥6.57 Billion	133.88%
Total Equity	CN¥4.91 Billion	100.00%

Cansino Biologics Inc Competitors by Market Cap

The table below lists competitors of Cansino Biologics Inc ranked by their market capitalization.

Company	Market Cap
BP PLC LSE:BP	$1.03 Billion
Zhe Jiang Kangsheng Co Ltd SHE:002418	$1.03 Billion
Sinoseal Holding Co Ltd SHE:300470	$1.03 Billion
Henan Hengxing Science & Technology Co Ltd SHE:002132	$1.03 Billion
Shenzhen Anche Technologies Co Ltd SHE:300572	$1.03 Billion
Cymbria Corporation TO:CYB	$1.03 Billion
Shanghai Research Institute of Building Sciences Group Co. Ltd A SHG:603153	$1.03 Billion
Shandong Fengyuan Chemical Co Ltd SHE:002805	$1.03 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Cansino Biologics Inc's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 5,274,604,094 to 4,909,872,000, a change of -364,732,094 (-6.9%).
Net loss of 378,883,997 reduced equity.
Dividend payments of 63,780,995 reduced retained earnings.
Share repurchases of 6,962,000 reduced equity.
New share issuances of 7,032,000 increased equity.
Other comprehensive income increased equity by 26,741,286.
Other factors increased equity by 51,121,612.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	CN¥-378.88 Million	-7.72%
Dividends Paid	CN¥63.78 Million	-1.3%
Share Repurchases	CN¥6.96 Million	-0.14%
Share Issuances	CN¥7.03 Million	+0.14%
Other Comprehensive Income	CN¥26.74 Million	+0.54%
Other Changes	CN¥51.12 Million	+1.04%
Total Change	CN¥-	-6.91%

Book Value vs Market Value Analysis

This analysis compares Cansino Biologics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 3.11x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 62.66x to 3.11x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2016-12-31	CN¥0.98	CN¥61.59	x
2017-12-31	CN¥2.78	CN¥61.59	x
2018-12-31	CN¥3.19	CN¥61.59	x
2019-12-31	CN¥5.94	CN¥61.59	x
2020-12-31	CN¥24.53	CN¥61.59	x
2021-12-31	CN¥32.31	CN¥61.59	x
2022-12-31	CN¥27.35	CN¥61.59	x
2023-12-31	CN¥21.38	CN¥61.59	x
2024-12-31	CN¥19.83	CN¥61.59	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Cansino Biologics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -7.72%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -44.77%
• Asset Turnover: 0.11x
• Equity Multiplier: 1.62x
Recent ROE (-7.72%) is above the historical average (-11.55%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2016	-23.24%	-608.31%	0.03x	1.52x	CN¥-71.30 Million
2017	-10.61%	-701.92%	0.01x	1.43x	CN¥-125.18 Million
2018	-27.53%	-12215.64%	0.00x	1.58x	CN¥-188.51 Million
2019	-10.66%	-1004.14%	0.01x	1.21x	CN¥-303.82 Million
2020	-6.53%	-1593.56%	0.00x	1.11x	CN¥-1.00 Billion
2021	23.94%	44.52%	0.36x	1.49x	CN¥1.11 Billion
2022	-13.48%	-87.90%	0.09x	1.70x	CN¥-1.58 Billion
2023	-28.11%	-415.23%	0.04x	1.77x	CN¥-2.01 Billion
2024	-7.72%	-44.77%	0.11x	1.62x	CN¥-869.87 Million

Industry Comparison

This section compares Cansino Biologics Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $4,691,234,838
Average return on equity (ROE) among peers: 6.16%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Cansino Biologics Inc (688185)	CN¥4.93 Billion	-23.24%	0.48x	$1.03 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078)	$903.62 Million	4.28%	2.45x	$1.16 Billion
Anhui Fengyuan Pharmaceutical Co Ltd (000153)	$1.22 Billion	5.35%	1.27x	$441.99 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423)	$9.87 Billion	20.71%	0.25x	$5.01 Billion
Livzon Pharmaceutical Group Inc (000513)	$1.07 Billion	3.83%	0.46x	$2.80 Billion
Wedge Industrial Co Ltd (000534)	$1.15 Billion	11.42%	1.59x	$3.04 Billion
Yunnan Baiyao Group Co Ltd (000538)	$9.03 Billion	25.71%	0.43x	$13.75 Billion
Hainan Haiyao Co Ltd (000566)	$275.57 Million	17.28%	1.12x	$947.33 Million
Tus Pharmaceutical Group Co Ltd (000590)	$231.22 Million	-38.13%	1.23x	$389.67 Million
Northeast Pharmaceutical Group Co Ltd (000597)	$4.29 Billion	2.31%	2.07x	$1.03 Billion
Jilin Aodong Pharmaceutical Group Co Ltd (000623)	$18.87 Billion	8.83%	0.08x	$3.32 Billion

About Cansino Biologics Inc

SHG:688185 China Drug Manufacturers - Specialty & Generic

Market Cap

$1.03 Billion

CN¥7.04 Billion CNY

Market Cap Rank

#9007 Global

#2413 in China

Share Price

CN¥61.59

Change (1 day)

+0.13%

52-Week Range

CN¥55.60 - CN¥88.48

All Time High

CN¥773.75